4D Molecular Therapeutics, Inc. (FDMT) Stock Price & Analysis

4D Molecular Therapeutics, Inc. (FDMT) closed at USD 12.78 on Thursday, October 29, 2026, down 1.16% on the day. The US market is currently closed (after-hours); this is not a live price.

The prior close was USD 12.93; the Oct 29, 2026 session ranged USD 12.57–13.46 on volume of 848,889 shares. Market capitalization is $706.02M, with a 52-week range of USD 6.96–16.93 (NMS). Source: Nexqual, retrieved October 29, 2026 at 21:08 UTC.

Also available as compact Markdown for AI agents: nexqual.com/FDMT.md

Key facts (FDMT)

• Last four reported quarters (through Jun 30, 2026): revenue $92.0M, net income -$179M (-194.7% margin) (SEC filings).
• Insider open-market sales, last ~7 months: 14 Form 4 filings, $5.3M; 0 not under a Rule 10b5-1 plan ($0K); 6 by opportunistic insiders (0 outside 10b5-1 plans), 0 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
• Analysts: Buy (mean 1.92 on a 1–5 scale) (12 analysts), mean target USD 28.09 (range 18–37).
• Total return with dividends: 1Y +12.9% vs S&P 500 +14.4%; 5Y -46.8% vs S&P 500 +79.1%.
• Next earnings: 2026-11-10, EPS estimate USD -1.05, revenue estimate $3.1M.

Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (FDMT)

Fiscal years end Dec. EPS is split-adjusted.

Valuation (price ÷ last four quarters, through Jun 30, 2026) (FDMT)

P/S 7.7x · EV/Sales 4.0x · P/B 1.7x · Earnings yield -25.38% · Net cash $342M · EV $364M

Insider sales (SEC Form 4, open-market, last ~7 months) (FDMT)

14 of 14 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.

% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).

Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.

Analysts (FDMT)

Consensus Buy (mean 1.92 on a 1–5 scale), 12 analysts; mean target USD 28.09 (low 18, high 37).

Rating changes, last 120 days:

Total return (dividends reinvested) (FDMT)

FDMT earnings history and stock reaction

EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).

FDMT recent SEC filings (last 120 days)

Source: SEC EDGAR. Quotes are the opening words of each item as filed; each form links to the filing. Insider Form 4 filings are listed in the insider sections.

FDMT suppliers, customers and competitors (named in its 10-K)

Quoted from the company's 10-K filed Mar 18, 2026.

FDMT company outlook (results filed Aug 13, 2026)

• “Based on our current operating plan, we estimate that our existing cash, cash equivalents and marketable securities, and expected payments under our collaboration agreement with Otsuka, will be sufficient to fund our operating expenses and capital expenditure requirements at least into the second half of 2028.”

Quoted word-for-word from the SEC 8-K results press release.

FDMT analyst estimates and revisions

FDMT options: expected move

Options price a move of about ±41.0% (±$5.15) by Nov 20, 2026, which includes earnings on Nov 10, 2026. Over the last 8 reports the stock moved ±3.1% on average.

30-day implied volatility 76.7% vs 69.2% realized over the last 30 trading days. Put/call ratio (volume) 0. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.

Key Statistics (as of October 29, 2026 at 21:08 UTC)

Technical Analysis (FDMT)

Nexqual's technical model rates FDMT "NEUTRAL" based on 2 bullish and 3 bearish signals across 127 daily candles, as of October 29, 2026 at 21:08 UTC.

Analyst Ratings (FDMT)

Wall Street analysts rate FDMT "Buy" based on 12 analysts, with a mean price target of USD 28.09 (range USD 18–37), per Nexqual as of October 29, 2026 at 21:08 UTC.

Earnings (FDMT)

Recent Earnings History

Source: Nexqual, October 29, 2026 at 21:08 UTC.

Financials & Fundamentals (FDMT)

Source: Nexqual, October 29, 2026 at 21:08 UTC.

Financial Health Score (FDMT)

Nexqual rates 4D Molecular Therapeutics, Inc.'s overall financial health "Weak" across five dimensions, as of October 29, 2026 at 21:08 UTC.

Ownership (FDMT)

Source: Nexqual, October 29, 2026 at 21:08 UTC.

Leadership (FDMT)

4D Molecular Therapeutics, Inc. is led by David H. Kirn, Co-Founder, President, CEO & Director, per Nexqual as of October 29, 2026 at 21:08 UTC.

Major Backers & Investors (FDMT)

Notable institutional backers of 4D Molecular Therapeutics, Inc. include Jupiter Topco LLC, RA Capital Management, L.P., Goldman Sachs, according to Nexqual as of October 29, 2026 at 21:08 UTC.

Active Investors

Index Funds (Passive)

Source: Nexqual, October 29, 2026 at 21:08 UTC.

From 4D Molecular Therapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-03-18)

Key Strengths & Strategy (as disclosed to the SEC)

• On October 31, 2025, we entered into a Collaboration and License Agreement ("Otsuka Collaboration and License Agreement") with Otsuka Pharmaceutical Co., Ltd. ("Otsuka"), pursuant to which we granted Otsuka exclusive rights to develop and commercialize 4D-150 for retinal vascular diseases, including wet AMD and DME, in Japan, China, Australia, and other Asia-Pacific ("APAC") markets.
• Our proprietary Therapeutic Vector Evolution Platform is based on the principles of directed evolution.
• Bolus anti-VEGF treatment of retinal vascular diseases represents global branded therapeutic markets of over $16 billion, with wet AMD and DME comprising approximately $14 billion.
• We believe our proprietary vectors will allow us to overcome known limitations of conventional AAV vectors, and to potentially address a broad range of diseases that affect both large and rare patient populations that cannot be addressed with conventional vectors.

Partnerships

• We are currently enrolling the Phase 2 portion of the AEROW Phase 1/2 clinical trial in people with CF with funding from and in collaboration with the CF Foundation.

Legal & Regulatory Risks (Item 1A, quoted)

• Changes in applicable regulatory guidelines may lengthen the regulatory review process, require us to perform additional studies or trials, increase our development costs, lead to changes in regulatory positions and interpretations, delay or prevent approval and commercialization of our product candidates or lead to significant post-approval limitations or restrictions.
• Adverse public perception or regulatory scrutiny of genetic medicine technology may negatively impact the developmental progress or commercial success of product candidates that we develop alone or with collaborators.
• Our product candidates may cause undesirable side effects or have other properties that could halt their clinical development, prevent their regulatory approval, limit their commercial potential or result in significant negative consequences.
• Adverse events or other undesirable side effects caused by our product candidates could cause us or regulatory authorities to interrupt, delay or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA or other comparable foreign regulatory authorities.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 29, 2026 at 21:08 UTC. This page is informational and not investment advice.

For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt